⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27784517 | 0.79 | — | — | |
| SCHEMBL18648257 | 0.69 | — | — | |
| SCHEMBL19491888 | 0.67 | — | — | |
| SCHEMBL1613820 | 0.67 | — | — | |
| SCHEMBL24688935 | 0.65 | TSHR (0.30) | — | |
| SCHEMBL1833058 | 0.64 | — | — | |
| SCHEMBL21327784 | 0.64 | — | — | |
| SCHEMBL13623711 | 0.64 | — | — | |
| SCHEMBL20713377 | 0.63 | — | — | |
| SCHEMBL38658611 | 0.63 | TSHR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-10207262-B2 | Chromium complex and catalyst therefrom | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180071725-A1 | CHROMIUM COMPLEX AND CATALYST THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-03-15 | — | — | US | disclosed |